<?xml version="1.0" encoding="UTF-8"?>
<p>The application of bacteriophages in therapy has been successful in treating: (i) MDR 
 <italic>A. baumannii</italic> infections (
 <xref rid="B79" ref-type="bibr">Schooley et al., 2017</xref>); (ii) against Mycobacterial infections (
 <xref rid="B19" ref-type="bibr">Dedrick et al., 2019</xref>); (iii) burn-wound infections caused by 
 <italic>P. aeruginosa</italic> (
 <xref rid="B34" ref-type="bibr">Jault et al., 2019</xref>); (iv) infections caused by 
 <italic>S. aureus</italic> (
 <xref rid="B21" ref-type="bibr">Fabijan et al., 2020</xref>); (v) Enterococcal infections (
 <xref rid="B40" ref-type="bibr">Khalifa et al., 2016</xref>); and (vi) against MDR 
 <italic>E. coli</italic> infections (
 <xref rid="B77" ref-type="bibr">Sarker et al., 2016</xref>; 
 <xref rid="B37" ref-type="bibr">Kakasis and Panitsa, 2019</xref>). Preparations of phage cocktails, phage banks, phage powders, and phage-derived endolysins as part of phage therapeutic approaches are possible and bring strategies closer to clinical applications (
 <xref rid="B59" ref-type="bibr">Manohar et al., 2019b</xref>,
 <xref rid="B60" ref-type="bibr">c</xref>).
</p>
